Zarnie Lwin

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Martin J. van den Bent, Hui Gan, Andrew B. Lassman et al. · Cancer Chemotherapy and Pharmacology · 2017 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17

Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression

Mairéad G. McNamara, Zarnie Lwin, Haiyan Jiang et al. · Journal of Neuro-Oncology · 2014 · 100 citations

Medicine, Oncology, Surgery +17

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with<i>EGFR</i>-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Andrew B. Lassman, Martin J. van den Bent, Hui Gan et al. · Neuro-Oncology · 2018 · 100 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated<i>MGMT</i>glioblastoma: the VERTU study

Hao‐Wen Sim, Kerrie L. McDonald, Zarnie Lwin et al. · Neuro-Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17